# Oncimmune Holdings plc Continues to make excellent progress

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-continues-make-excellent-progress/412745656
- Published: 2018-02-13T07:11:14+00:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON:ONC), a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT® liquid biopsy platform technology,
today announced its interim results for the half year ended 30 November 2017.

**Corporate & Operational highlights (including post-period end)**

EarlyCDT®-Lung Commercial Progress

· Framework agreement with Genostics Company Limited (“Genostics”) for China signed

o Exclusive licence for the distribution, manufacturing and future development of
all products related to the EarlyCDT® platform

o Royalty payments of 8% to 12.5% with minimum royalties over the first six years
post market entry of £15.7 million, and £5 million (index linked) per year thereafter

o £10m equity investment in Oncimmune with first investment tranche of £7m completed
on 29 January 2018

· New agreements signed in multiple territories

o EarlyCDT®-Lung kit has minimum payment guarantees of £7.9m over the next five 
years in Asia Pacific (not including China).

o EarlyCDT®-Lung kit has minimum sales commitment of approximately £2.0m over the
next five years in Europe

· First commercial batches of the EarlyCDT®-Lung kit shipped to distributors for
introductory testing prior to full market release

· Distributor base in the US being trained for the sale of our EarlyCDT®-Lung test

· Preliminary distribution partnership progressing well with a major US pulmonary
sales force for the use of EarlyCDT®-Lung in assessing indeterminate lung nodules:

o Initial phase is expected to complete by the end of the month

o Following completion, the parties will assess the results and, if successful, 
it is expected that this should lead to a distribution agreement for the U.S. pulmonologists

· “Finger stick” test launched, increasing speed and simplicity of EarlyCDT®-Lung
test

**R&D and Trials**

· Development of the kit version of our EarlyCDT® tests is helping expand our geographical
reach and we expect to make significant progress on this going forward

· Validated EarlyCDT®-Liver test and on track to begin commercial sales in H1 2018

· NHS lung cancer screening trial is fully recruited: 12,210 patients with final
study results in 2019

Personalised Medicine & Companion Diagnostics

· Presented data on the use of Oncimmune’s technology to predict disease recurrence
in patients undergoing immunotherapy for malignant melanoma in collaboration with
Scancell Holding plc

· Autoantibody “fingerprint” technology development progressing well; first publications
presented at the IASLC in November 2017

o Reaffirmed the early detection capabilities of the EarlyCDT® platform with patients
on average showing an early detection lead-time of four years

**Board Changes**

· Appointment of Dr. Annalisa Jenkins to the Company’s Board as an Independent Non-
Executive Director

**Financial Highlights**

· Revenues of £0.1m (2016: £0.1m) generated from early sales of the EarlyCDT®-Lung
test

· Loss before one-off and non-cash items of £3.04m (2016: £2.3m) reflecting recruitment
of staff, product development and commercialisation activities

· £5.0m raised from new and existing investors

· Cash balance at the period end was £6.3m (H1 2016: £7.6m)

· Post period end receipt of first tranche equity subscription of £7.0m from Genostics
making the cash balance £11.8m at the time of these results

> **Geoffrey Hamilton-Fairley, CEO of Oncimmune Holdings Plc said:** “Oncimmune 
> continues to make excellent progress in delivering on the potential of our platform
> to detect up to four years earlier than other methods based on a simple, robust,
> blood test – a liquid biopsy.
> We have recently entered an exclusive distribution and product development agreement
> in China which includes a £10m equity investment and £15.7m in minimum royalties.
> We have now secured agreements for 12 countries with minimum sales commitments
> of £25.6m. We have also entered a preliminary distribution partnership with a 
> major US pulmonology salesforce which is progressing well and, if successful, 
> should lead to a significant distribution agreement focused on the risk detection
> of indeterminate pulmonary nodules – a large and growing market.
> With our R&D programme delivering new tests and commercial opportunities in personalised
> medicine and companion diagnostics, we are excellently placed to deliver value
> in the medium and long term.”

Share on:
